anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This study aimed to assess the quality of randomized controlled trials (RCTs) that have reported the use of acupuncture for the treatment of post-stroke aphasia (PSA).
METHODS: We systematically searched PubMed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Wanfang data Information Site, and China Science and Technology Journal Database from January 2013 to June 2023. RCTs utilizing acupuncture as an intervention for the treatment of post-stroke aphasia were included in this study. The overall quality score (OQS) of RCTs was independently evaluated by two researchers using the Consolidated Standards for Reporting Trials (CONSORT) and the Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA) guidelines, with the agreement between researchers calculated using Cohen's kappa statistics.
RESULTS: In conclusion, we included 38 RCTs in this study. The median OQS of the 38 RCTs was 13 (minimum 8, maximum 20) based on the CONSORT statement. Out of all CONSORT items, 10 (27%) had a positive rate of greater than 80%, while 17 (46%) had a positive rate of less than 10%. The median OQS of the 38 RCTs was 12 (minimum 6, maximum 14) based on the STRICTA guideline. Within the STRICTA guideline, 6 items (35%) had a positive rate of greater than 80%, and 3 items (18%) had a positive rate of less than 10%. Most items based on the CONSORT and STRICTA guidelines were observed to have a perfect or good degree of agreement.
CONCLUSIONS: The overall reporting quality of RCTs for acupuncture treatment of PSA was found to be suboptimal. Notably, the reporting quality of the STRICTA guideline is higher compared to the CONSORT statement. Therefore, strict adherence to both the CONSORT and STRICTA statements is recommended to enhance the quality of RCT reports on acupuncture treatment for post-stroke aphasia.
A CPU of a medical care support server functions as a reception unit, an RW control unit, and a screen output control unit. The reception unit receives precaution information on an owner of a pet as owner information. The RW control unit performs control to store the precaution information in a storage device. The screen output control unit outputs a pet health management screen on which a balloon display region, which is a display region dedicated to the precaution information, is provided. An information mark indicating presence of the precaution information is displayed on the health management screen. The balloon display region is displayed only in a case where the information mark is selected.
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by pulmonary and systemic congestion resulting from left ventricular diastolic dysfunction and increased filling pressure. Currently, however, there is no evidence on effective pharmacotherapy for HFpEF. In this study, we aimed to investigate the therapeutic effect of total xanthones extracted from Gentianella acuta (TXG) on HFpEF by establishing an high-fat diet (HFD) + L-NAME-induced mouse model. Echocardiography was employed to assess the impact of TXG on the cardiac function in HFpEF mice. Haematoxylin and eosin staining, wheat germ agglutinin staining, and Masson's trichrome staining were utilized to observe the histopathological changes following TXG treatment. The results demonstrated that TXG alleviated HFpEF by reducing the expressions of genes associated with myocardial hypertrophy, fibrosis and apoptosis. Furthermore, TXG improved cardiomyocyte apoptosis by inhibiting the expression of apoptosis-related proteins. Mechanistic investigations revealed that TXG could activate the inositol-requiring enzyme 1α (IRE1α)/X-box-binding protein 1 (Xbp1s) signalling pathway, but the knockdown of IRE1α using the IRE1α inhibitor STF083010 or siRNA-IRE1α impaired the ability of TXG to ameliorate cardiac remodelling in HFpEF models. In conclusion, TXG alleviates myocardial hypertrophy, fibrosis and apoptosis through the activation of the IRE1α/Xbp1s signalling pathway, suggesting its potential beneficial effects on HFpEF patients.
Following completion of the first 8-week double-blind study, 63 patients entered an open-label study extension where they were treated with risperidone for 4 or 6 months (depending on whether they received risperidone or placebo in the double-blind study). During this open-label treatment period, patients were maintained on a mean modal dose of risperidone of 1.8 to 2.1 mg/day (equivalent to 0.05 to 0.07 mg/kg/day). 

Patients who maintained their positive response to risperidone (response was defined as ≥ 25% improvement on the ABC-I subscale and a CGI-C rating of ‘much improved’ or ‘very much improved’) during the 4 to 6 month open-label treatment phase for about 140 days, on average, were randomized to receive risperidone or placebo during an 8-week, double-blind withdrawal study (n = 39 of the 63 patients). A pre-planned interim analysis of data from patients who completed the withdrawal study (n = 32), undertaken by an independent Data Safety Monitoring Board, demonstrated a significantly lower relapse rate in the risperidone group compared with the placebo group. Based on the interim analysis results, the study was terminated due to demonstration of a statistically significant effect on relapse prevention. Relapse was defined as ≥ 25% worsening on the most recent assessment of the ABC-I subscale (in relation to baseline of the randomized withdrawal phase).
A dental filling cement comprises zinc oxide cement powder containing 0.1%-1% of triamcinolone acetonide and 1.5%-3% of tetracycline demethyltetracycline or demethylchlortetracycline. For setting the cement a hardening agent such as eugenol (which may be mixed with rectified oil of turpentine) is added immediately before use.  The cement may include Canada balsam or rosin.  Before applying the cement the tooth cavity may be temporarily filled with a hydrophilic paste comprising triamcinolone acetonide and tetracycline, demethyltetracycline or demethylchlortetracycline with polyethylene glycol.  The cement, hardening agent and hydrophilic paste may be packed separately in a pack.  In filling large cavities, the dental cement is covered with a phosphate cement which may comprise zinc oxide cement powder and a hardening catalyst containing concentrated phosphoric acid and aluminium phosphate.
Tumor antigen-specific CD8+ T cells from draining lymph nodes gain an accumulating importance in mounting anti-tumor immune response during tumorigenesis. However, in many cases, cancer cells form metastatic loci in lymph nodes before further metastasizing to distant organs. To what extent the local and systematic CD8+ T cell responses were influenced by LN metastasis remains obscure. To this end, we set up a murine LN metastasis model combined with a B16F10-GP melanoma cell line expressing the surrogate neoantigen derived from lymphocytic choriomeningitis virus (LCMV), glycoprotein (GP), and P14 transgenic mice harboring T cell receptors (TCRs) specific to GP-derived peptide GP33-41 presented by the class I major histocompatibility complex (MHC) molecule H-2Db. This protocol enables the study of antigen-specific CD8+ T cell responses during LN metastasis. In this protocol, C57BL/6J mice were subcutaneously implanted with B16F10-GP cells, followed by adoptive transfer with naive P14 cells. When the subcutaneous tumor grew to approximately 5 mm in diameter, the primary tumor was excised, and B16F10-GP cells were directly injected into the tumor draining lymph node (TdLN). Then, the dynamics of CD8+ T cells were monitored during the process of LN metastasis. Collectively, this model has provided an approach to precisely investigate the antigen-specific CD8+ T cell immune responses during LN metastasis.
Gentamicin Sulfate in 0.9% Sodium Chloride Injection in VIAFLEX PLUS plastic container is available in the following sizes and concentrations.

Do not remove unit from overwrap until ready for use. The overwrap is a moisture barrier. The inner bag maintains the sterility of the product. After removing overwrap, check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.
[PROBLEMS] To provide a compound having SGLT1 and/or SGLT2 inhibiting potency that can be used as a preventive or therapeutic agent for diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complication, obesity, etc. [MEANS FOR SOLVING PROBLEMS] There are provided 1-substituted-7-(β-D-glycopyranosyloxy)(aza)indole compounds of the general formula (I), prodrugs or pharmacologically acceptable salts thereof, and hydrates or solvates thereof. [Chemical formula 1] (I) wherein R1 is a halogen atom, etc.; n is an integer of 0 to 3; R2 is a halogen atom, etc.; X is a nitrogen atom or carbon atom having a hydrogen atom, etc. bonded thereto; Q is an alkenylene group or alkylene group optionally having an oxygen atom or sulfur atom in its chain; and A is an optionally substituted aryl or heteroaryl group.
BACKGROUND: Pulmonary hypertension is a serious disease. Emerging studies have shown that M2 macrophages play an essential role in pulmonary hypertension; however, their mechanism of action is uncertain.
METHODS: Four GEO datasets were downloaded. The differentially expressed genes (DEGs) were obtained using the limma package. Simultaneously, the Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) algorithm and weighted gene co-expression network analysis (WGCNA) were used to get the information about M2 macrophage-related modules. Potential key genes were obtained by intersecting DEGs with M2 macrophage-related module genes (M2MRGs), and finally the area under the curve (AUC) was calculated. Rats were exposed to hypoxia condition (10 % O2) for 4 weeks to induce PH. Subsequently, potential key genes with AUC>0.7 were analyzed by quantitative real-time polymerase chain reaction and Western blot using normoxia and hypoxia rat lungs. We knocked down EPHA3 in Raw264.7 cells and detected the protein expression of M2 macrophage markers including arginase 1 (ARG1) and interleukin 10 (IL-10), phospho-protein kinase B (P-Akt), and protein kinase B (Akt) to explore the downstream pathways of EPHA3.
RESULTS: Seven potential hub genes were detected by intersecting M2MRGs and DEGs. Six genes with AUC values above 0.7 were used for further exploration. The expression of EPHA3 mRNA and protein was significantly more upregulated in rats with hypoxia than in rats with normoxia. The expression levels of IL10, ARG1, and P-Akt/Akt decreased after knocking down EPHA3.
CONCLUSIONS: This study suggested that the activation of the P-Akt/Akt signaling pathway promoted by EPHA3 played an essential role in the progression of pulmonary hypertension.
A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissuelacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the scalp or penis. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride. This preparation when applied nightly to scalp tissue lacking sufficient hair for a period of time causes substantial growth of hair on the scalp. Further, when applied to the penis of a subject with erectile dysfunction causes restoration of normal sexual function.
As a food contaminant that can be quickly absorbed through the gastrointestinal system, furan has been shown to disrupt the intestinal flora and barrier. Investigation of the intestinal toxicity mechanism of furan is of great significance to health. We previously identified the regulatory impact of salidroside (SAL) against furan-provoked intestinal damage, and the present work further explored whether the alleviating effect of SAL against furan-caused intestinal injury was based on the intestinal flora; three models, normal, pseudo-germ-free, and fecal microbiota transplantation (FMT), were established, and the changes in intestinal morphology, barrier, and inflammation were observed. Moreover, 16S rDNA sequencing observed the variation of the fecal flora associated with inflammation and short-chain fatty acids (SCFAs). Results obtained from the LC-MS/MS suggested that SAL increased furan-inhibited SCFA levels, activated the mRNA expressions of SCFA receptors (GPR41, GPR43, and GPR109A), and inhibited the furan-activated TLR4/MyD88/NF-κB signaling. Analysis of protein-protein interaction further confirmed the aforementioned effects of SAL, which inhibited furan-induced barrier damage and intestinal inflammation.
PURPOSE:To obtain a novel compound useful for treating infectious diseases due to an acid-fast bacterium, especially Mycobacterium tuberculosis, Mycobacterium avium or Mycobacterium intracellulare. CONSTITUTION:The compound is expressed by the formula (R1 is octyl or pivaloyloxymethyl), e.g. octyl pyrazinecarboxylate. This compound expressed by the formula is obtained by reacting pyrazinecarboxylic acid with 1-octanol in the presence of a strong acid (e.g. sulfuric acid) at 50-150 deg.C (in case R1 is octyl group). The compound is capable of manifesting excellent therapeutic effects on infectious diseases due to an acid-fast bacterium, especially Mycobacterium tuberculosis (abbreviated to M. tuberculosis), Mycobacterium avium (abbreviated to M. avium) or Mycobacterium intracellulare (abbreviated to M. intracellulare) or mixed infectious disease of two or more of the acid-fast bacteria, e.g. M. avium complex infectious disease.
BACKGROUND: Sestrins have been implicated in regulating aging in various organs through multiple pathways. However, their roles in ovarian aging remain unrevealed.
METHODS: Female Sestrin1-/-, Sestrin2-/-, and Sestrin3-/- mice were generated using the CRISPR-Cas9 system. Body weights, little sizes, ovarian weights, estrous cyclicity, and follicle number in female mice were observed. ELISA was utilized to measure serum anti-Müllerian hormone (AMH) levels. Real time PCR, western blot, immunofluorescence, and Masson trichrome staining were employed for assessment of aging-related change.
RESULTS: The deletion of Sestrin 1, 2, or 3 had no discernible impact on body weights,or serum AMH levels in female mice at the age of 12 months. And there were no discernible differences in litter sizes or estrous cyclicity which were assessed at the age of 8 months. At the age of 12 months, no significant differences were observed in ovarian weights or follicle numbers among the knockout mice. Consistently, the extent of fibrosis within the ovaries remained comparable across all experimental groups at this age. Additionally, autophagy, apoptosis, DNA damage, and inflammation within the ovaries were also found to be comparable to those in wild-type mice of the same age.
CONCLUSIONS: The loss of Sestrin 1, 2, or 3 does not exert a noticeable influence on ovarian function during the aging process. Sestrin1, 2, and 3 are not essential for female fertility in mice.
The invention belongs to the technical field of medicines, and relates to a docetaxel derivative, and a preparation method and application thereof. The docetaxel derivative is triphenylphosphine-docetaxel (TD), and is prepared by esterification reaction of docetaxel and 4-carboxybutyltriphenyl phosphonium bromide under the catalysis of EDC and DMAP. Docetaxel and mitochondrion targeting radical triphenylphosphine are connected through ester bond, and the structure is as follows. The multiphase paclitaxel derivative prepared by the invention has simple and feasible synthesis method, and provides a new idea for mitochondrial targeting drug delivery. The paclitaxel derivative is encapsulated in the liposome, and the preparation method is simple and easy to implement, good in reproducibility and high in stability. The PEG modified paclitaxel derivative liposome can prolong the circulation time in blood, and can better release antitumor drugs at tumor sites due to a pH sensitive rupture mechanism.
PURPOSE:To provide a novel cosmetic containing the water-soluble extract of coconut fruits as an active ingredient, simultaneously having a beautifully whitening action, an antiinflammatory action and a water retention which are highly stable, and preferable also on safety. CONSTITUTION:Coconut fruits are ground and then extracted with water or with the water and a water-soluble solvent under heating, and the extract is concentrated. The cosmetic simultaneously having a beautifully whitening action, an inflammatory action and a water-retaining force contains the concentrated extract as a raw material. The base material is used as a raw material to provide the cosmetic such as a beauty water, a cream, an emulsion, a shampoo. a foundation, a lip cream, a lip stick. etc. The water-soluble extract of the coconut fruits is preferably used in an amount of 0.1-5.0wt.% based on the total amount of the cosmetic.
An antibiotic with an antibacterial spectrum closely related to that of penicillin is produced by the surface culture of Penicillium cyaneofulvum ATCC 11923 on a beef infusion broth containing 1 per cent glucose at 20-25 DEG  C. for 7 days.ALSO:The invention relates to noxiversin which is a protein substance derived from the albumen fraction of a culture of Penicillium cyaneofulrum ATCC 11923 free of mycelium and globulin, effective in detoxifying toxins, effective as a toxoiding agent, non-dialysable, non-antibiotic, non-antigenic, non-toxic, its detoxifying and toxoiding activity not being interfered with by Clarase (penicillin inactivating substance), thermolabile, free of copper sulphate precipitated material, free of dialysable substances, its toxin inactivating activity being attributable to its capability to act directly upon the toxia molecule in contrast to a blocking action.  P. cyanco fulrum is surface cultured on glucose beef infusion broth for 7 days at 20 DEG to 25 DEG  C.  Less suitable is a medium containing malt extract, neopeptone and glucose.  The mycelium is filtered off, the pH of the culture filtrate adjusted to pH 7.0, ammonium sulphate added to 48 per cent concentration and the precipitated globulin removed by centrifugation.  The clear liquid is saturated with ammonium sulphate and the active albumen fraction precipitates and is removed.  This is suspended in saline and dialysed against saline for 48 hours at 5 DEG C. and negative pressure of - 6 mm. Hg. The dialysed albumen fraction may then be lyophilized and stored in ampoules at 4-10 DEG  C. Alternatively, a ten-fold purification is obtained by adding 1 per cent copper sulphate to an aqueous solution of the above albumen fraction and removing the inactive precipitate which is toxic to animals.  The supernatant fluid is dialysed against saline to remove excess copper sulphate. Noxiversin is thermolabile, being completely inactivated in solution after 30 minutes at 70 DEG  C.  It is inactivated by fresh normal serum.  It is used in the preparation of toxoids and antitoxic sera for medicinal and veterinary use.
The present invention relates to a Chinese medicine powder (paste) for curing angiitis-Yankang Powder (Paste). Said Chinese medicine is made up by using the Chinese medicinal materials of bushy knotweed root, coptis root, pearl powder, bletilla tuber, dragon's blood, borneol and dahurian angelica root as raw material, and the above-mentioned pure Chinese medicine preparation is mixed with puccoon oil, can be made into the medicine for external application. Said Chinese medicine possesses the functions of germicidal and relieving inflammation, stanching-blood and engendering flesh, promoting the growth of granulation tissue, promoting capillary regeneration and regrowth of severed finger (toe). Besides, said medicine also can be used for curing gangrene due to angiitis, ulcer, trauma and scald, etc. free from toxic side effect. Its total effective rate is 90%, and its cure rate is 80%.
FABHALTA, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis (caused by any serogroup, including non-groupable strains), and Haemophilus influenzae type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of FABHALTA treatment is contraindicated in patients with unresolved serious infections caused by encapsulated bacteria.

Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of FABHALTA, according to the current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with FABHALTA. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent FABHALTA therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including FABHALTA. The benefits and risks of treatment with FABHALTA, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.

Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of FABHALTA in patients who are undergoing treatment for serious infections, depending on the risks of interrupting treatment in the disease being treated. 

FABHALTA is available only through a restricted program under a REMS [see Warnings and Precautions (5.2)].
The intensity setting for pulse amplitude will be adjusted to the participant's tolerance (if a sensation is felt) to a maximum level of 3 on the dial indicator. The remaining settings will be stored in the device and will not need to be set for each treatment. Participants and guardians will be instructed to adjust intensity to highest level of tolerance each time the device is used and level will be logged.
Study is planned as only 1 group of patient with hyperkalemia. Pre and post treatment data obtained from patients via ECG, ECHO and laboratory values will be recorded and evaluated in terms of literature. Patient-based findings will also be recorded and evaluated.